
## **Trustees’ Annual Report for the period** 

**From 01 January 2025      Period start date   To 31 December 2025 Period end date** 

**Charity name: Foundation for Angelman Syndrome Therapeutics UK Charity registration number: 1167984** 

## **Objectives and Activities** 

||SORP reference||
|---|---|---|
|Summary of the purposes of<br>the charity as set out in its<br>governing document|Para 1.17|The objects of the CIO are:-<br>1. the advancement of health for the benefit<br>of the public by the provision of support<br>towards research into Angelman syndrome<br>including their treatment and cure, and the<br>publication of the useful results of such<br>research; and<br>2. the relief of those in need of care,<br>assistance and support as a consequence of<br>living with Angelman Syndrome.|
|Summary of the main<br>activities in relation to those<br>purposes for the public<br>benefit, in particular, the<br>activities, projects or services<br>identified in the accounts.|Para 1.17 and<br>1.19|Foundation for Angelman Syndrome<br>Therapeutics UK continues to assist Oxford<br>University in funding a Natural History Study<br>for Angelman Syndrome.  The study has<br>been funded by FAST UK for 4 years and<br>has now been extended by another 2 years<br>with the recruitment of 15 more patients. As<br>well as this, FAST UK is funding to support<br>the delivery of weekend lumbar puncture<br>(LP) clinics as part of the Angelman<br>syndrome clinical research programme at<br>the University of Oxford.|
|Statement confirming<br>whether the trustees have<br>had regard to the guidance<br>issued by the Charity<br>Commission on public<br>benefit|Para 1.18|The trustees have had regard to the<br>guidance issued by the Charity Commission<br>on public benefit.|



## **Additional information (optional)** You may choose to include further statements where relevant about: 

SORP reference Para 1.38 Policy on grant making Para 1.38 



Policy on social investment including program related investment Para 1.38 Contribution made by volunteers Other 

## **Achievements and Performance** 

||SORP reference||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identifying the difference the<br>charity’s work has made to<br>the circumstances of its<br>beneficiaries and any wider<br>benefits to society as a<br>whole.|Para 1.20|Fund raising activities and donations<br>through-out the financial period have raised<br>income of £29,329.<br>FAST UK is linked with FAST US who are<br>making huge steps into finding a cure for<br>Angelman Syndrome through scientific<br>research, and FAST UK have continued to<br>support FAST US’s efforts with this.<br>FAST UK has committed to fund the Natural<br>History Study in conjunction with Oxford<br>University for another 5 years with an<br>additional year for data analysis.<br>Funding of £25,732 per year will be provided<br>in the years 2026 to 2031 inclusive. FAST<br>UK have also committed to funding an AS<br>weekend lumbar puncture clinic to ensure<br>trials are kept on track and in timelines at a<br>cost of £108,000 over 3 years with a start<br>date of June 2026.<br>The NHS continues to be a success with<br>useful and meaningful data. Clinical trials are<br>also currently taking place in Oxford with<br>more pharma companies looking to start<br>their trials next year.|



**Additional information (optional)** You may choose to include further statements where relevant about: 

Achievements against Para 1.41 objectives set 



|Performance of fundraising<br>activities against objectives<br>set|Para 1.41||
|---|---|---|
|Investment performance<br>against objectives|Para 1.41||
|Other|||





## **Financial Review** 

|**Financial Review**|||
|---|---|---|
|Review of the charity’s<br>financial position at the end<br>of the period|Para 1.21|At the end of the period the charity was in a<br>net asset position of £347,206**.**|
|Statement explaining the<br>policy for holding reserves<br>stating why they are held|Para 1.22|There is no reserves policy, and no<br>reserves are held.|
|Amount of reserves held|Para 1.22|Nil.  Cash at year end was £347,206, none<br>of which is specifically held in reserves.|
|Reasons for holding zero<br>reserves|Para 1.22|The charity is small, with one employee and<br>has minimal fixed costs or expenses, and is<br>in a positive cash position and as such no<br>reserves are required.|
|Details of fund materially in<br>deficit|Para 1.24|N/A|
|Explanation of any<br>uncertainties about the<br>charity continuing as a going<br>concern|Para 1.23|There are no uncertainties over the charity’s<br>ability to continue as a going<br>concern.  There are substantial cash<br>reserves to support the on-going level of<br>expenditure.|



**Additional information (optional)** You may choose to include further statements where relevant about: The charity’s principal sources of funds (including Para 1.47 any fundraising) Investment policy and objectives including any Para 1.46 social investment policy adopted A description of the principal Para 1.46 risks facing the charity Other 



## **Structure, Governance and Management** 

|Description of charity’s<br>trusts:|||
|---|---|---|
|Type of governing document<br>(trust deed, royal charter)|Para 1.25|Constitution|
|How is the charity<br>constituted?<br>(e.g unincorporated<br>association, CIO)|Para 1.25|A Charitable Incorporated Organisation|
|Trustee selection methods<br>including details of any<br>constitutional provisions e.g.<br>election to post or name of<br>any person or body entitled<br>to appoint one or more<br>trustees|Para 1.25|Apart from the first charity trustees, every<br>trustee must be appointed by a resolution<br>passed at a properly convened meeting of<br>the charity trustees.|



## **Additional information (optional)** You may choose to include further statements where relevant about: 

||||
|---|---|---|
|Policies and procedures<br>adopted for the induction and<br>training of trustees|Para 1.51||
|The charity’s organisational<br>structure and any wider<br>network with which the<br>charity works|Para 1.51||
|Relationship with any related<br>parties|Para 1.51||
|Other|||



## **Reference and Administrative details** 

|Charity name|Foundation for Angelman Syndrome Therapeutics UK|
|---|---|
|Other name the charity uses|FAST UK|
|Registered charity number|1167984|
|Charity’s principal address|13 Inglethorpe Street,<br>London,<br>SW6 6NS|
|||





**Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**<br>**year**|**Nam**<br>**e of**<br>**pers**<br>**on**<br>**(or**<br>**body**<br>**)**<br>**entitl**<br>**ed to**<br>**appo**<br>**int**<br>**trust**<br>**ee (if**<br>**any)**|
|---|---|---|---|---|
||Thomas Keogh|Chair|||
||Tamsin Keogh||||
||Antonia Felix||||
||Louise Prince||||
||Katharine Hamilton||||
||Julien de Bournet||||
||Sarah Washbrook||16/06/2016 -present||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
|20|||||



– Corporate trustees names of the directors at the date the report was approved 

**Director name** 

Name of trustees holding title to property belonging to the charity 

**Trustee name Dates acted if not for whole year** 



## **Funds held as custodian trustees on behalf of others** 

|Description of the assets<br>held in this capacity|N/A|
|---|---|
|Name and objects of the<br>charity on whose behalf the<br>assets are held and how this<br>falls within the custodian<br>charity’s objects|N/A|
|Details of arrangements for<br>safe custody and<br>segregation of such assets<br>from the charity’s own assets|N/A|



## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

||**Type of**<br>**adviser**<br>**Name**<br>**Address**|**Type of**<br>**adviser**<br>**Name**<br>**Address**|**Type of**<br>**adviser**<br>**Name**<br>**Address**|
|---|---|---|---|
|||||
|||||
|||||
|||||
||**Name of chief executive or names of senior staff members (Optional information)**|||
|||||
|||||





## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees Signature(s) Full name(s)** Thomas Keogh **Position (eg** Chair **Secretary, Chair, etc) Date** 26/10/2026 




**Charity Name No (if any)** Foundation for Angelman Syndrome Therapeutics UK 1167984 **Receipts and payments accounts CC16a For the period** Period start date Period end date **To from** 01-Jan-25 31-Dec-25 

|**Section A Receipts and payments**|**Section A Receipts and payments**||||||
|---|---|---|---|---|---|---|
|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**29,329**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**29,329**<br>**-**<br>**-**<br>**-**<br> **29,329**<br>**4,182**<br>**562**<br>**442**<br>**1,000**<br>**10,437**<br>**125**<br>**-**<br>**-**<br>**-**<br> **16,748**<br>**-**<br>**-**<br> **-**<br> **16,748**<br>**12,581**<br>**-**<br>**334,625**<br>**347,206**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Total funds**<br>**to the nearest £**<br>**29,329**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**29,329**<br>**-**<br>**-**<br>**-**<br>**29,329**<br>**4,182**<br>**562**<br>**442**<br>**1,000**<br>**10,437**<br>**125**<br>**-**<br>**-**<br>**-**<br>**16,748**<br>**-**<br>**-**<br>**-**<br>**16,748**<br>**12,581**||**Last year**<br>**to the nearest £**|
|Fundraisingand Donations|**29,329**|||||**183,082**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|**29,329**|||||**183,082**|
||||||||
|**A2 Asset and investment sales,**<br>**(see table).**|||||||
||**-**||||||
||**-**|||||**-**|
|~~**_Sub total_**~~|**-**|||||**-**|
|**_Total receipts_ **<br>**A3 Payments**|||||||
|||||||**183,082**|
||||||||
|Salary,Pension and Related Expenses|**4,182**|||||**10,151**|
|Incurred raisingdonations|**562**|||||**562**|
|Marketing,Advertisingand Postage|**442**|||||**1,106**|
|Website Cost|**1,000**|||||**1,000**|
|StagingFundraisingevents|**10,437**|||||**25,008**|
|Subscriptions and Memberships|**125**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_ **|**16,748**|||||**37,827**|
||||||||
|**A4 Asset and investment**<br>**purchases, (see table)**|||||||
||**-**||||||
||**-**||||||
|**_Sub total_ **|**-**|||||**-**|
|**_Total payments_ **<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**|||||||
|||||||**37,827**|
||||||||
||**12,581**|**-**|**-**|**12,581**||**145,255**|
||**-**|**-**|**-**|**-**||**-**|
||**334,625**|**-**|**-**|**334,625**||**189,370**|
||**347,206**|**-**|**-**|**347,206**||**334,625**|



CCXX R1 accounts (SS) 

13/10/2026 

1 



|**Section B Statement of assets and liabilities at the end of the period**|**Section B Statement of assets and liabilities at the end of the period**|**Section B Statement of assets and liabilities at the end of the period**||
|---|---|---|---|
|**Categories**<br>Signed by one or two trustees on<br>behalf of all the trustees<br>**B5 Liabilities**<br>**B3 Investment assets**<br>**B2 Other monetary assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B1 Cash funds**|**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>Cash at Bank<br>**Details**<br>**Details**<br>**Details**<br>Signature|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**347,206**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**347,206**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Tom Keogh<br>Katharine Hamilton|**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
|||Tom Keogh|12/10/2026|
|||Katharine Hamilton|12/10/2026|



CCXX R2 accounts (SS) 

13/10/2026 

2 



CHARITY COMM15510NI •wnln•f•
FOR ENGIAND APIO WAIES
qr